The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
At no point has it been mentioned that NCYT ar exited up in the GLP review. However NCYTs contract was awarded during the same time period. As time has went on and that case got dragged on, the suggestion has gained legs.
Personally I dont believe it is because if it were, other parties like the GLP would have released it.
Kiltedscotsman, "his name also appears on the contested contract with the DHSC."
Thats *******s because he joined the company in January 2021 - months after the contract was signed. The PE article is shut slinging and tbats it. Theyre trying it on from every angle amd the company would do well to not lower themselves to a response.
Hi Drb, I didnt say therell be nothing until April. Infact i think there could be plenty of news however I was pointing out that that is what DA was implying. The RNS and his interview only suggests what the long term plan will be.
No post period highlights, no operational updates since he started in October and he's suggesting we'll hear more In April. 6 months is a long time on any market.
Hi B2, I also thought the proactive interview was a little sloppy, but I dont think it was negative vibes as much as a lack of short-term forecast.
Having digested the RNS, it says absolutely nothing about developments since he took over. Operational highlights are all pre-october.
He's saying it'll be April before he adds some colour to the long term plan. We don't get any update on the DHSC timeline and hes talking Q4 for other products to come on line.
So its a black hole between October 2021 and April 2022. I cant help think there's more but its extremely difficult to stomach at these levels.
W@nk3ers are out in force again this weekend.
Must be something big coming here.
Whoever is looking to buy in here is paying shift rates by the look of it.
Thanks Gazman
HKK, Not necessarily. They could clear that stock down in December and not be obliged to announce it until the results end of Jan. They didn't have to announce the exceptional cost until September results amd they would have known about it since Q1/Q2.
Having said that, I dont believe they will clear that stock (and the related exceptional cost) off the balance sheet if there's a chance they can claim it back via the dispute resolution.
Youre not on your own Kaeren.
Not long now until we see whats really happening.
Deffo! Testing was through the roof July and August too and we haven't had any update on revs for that period.
Revenue could be materially higher. Because of the unpredictable nature of covid testing, they have an excuse not to raise their guidance.
The guidance was also reiterated in August and September.
In my mind the CTDA RNS's were firmly addressing losses that are associated with DHSC red tape.
Im confident itll be well over it but how much profit amd cash will be the bigger question. Unless we get a resolution between now and then, theres a £12m deficit from H1 to overcome.
Hi Neil, I believe those CTDA RNS' detail the government's direct impact on NCYT revenue and are therefore tied up with the dispute and any damages that may come out of it.
I also believe that the incessant tweeting of the Pathflow LFT is a nod to recent UK shortages and the bottleneck on those approvals.
People focusing on the SP whilst the market cap is less than £200m.
Less than 2x sales.
Even if they didn't sell anything in H2, the £54m sales in H1 would result in a much larger market cap for ANY of NCYT peers.
The lack of communication or direction is causing uncertainty but they can't stay silent forever.
Spot on KT.
Hospitals and critical care settings will require any and all PCR capacity so travel and general public (who show no symptoms) will get a pass with LFTs.
Company will still be selling everything they can make.
Thanks Exmex, a lot of tosh written here over the last week but good to see sensible posters continue to contribute!
And yet, even at 30% down theyre still trading at 50m mcap. 5 X annual sales!
By that same measure NCYT should be trading at 700p/500m based on underlying business (i.e no disputed/dhsc revs).
Only a matter of time.
Its difficult to mandate vaccines as it discriminates against the immuno compromised.
Northern Ireland have introduced covid passports for the hospitality sector and a lot of people are up in arms, yet a negative LFT will suffice
Get well soon Poidster!
Really good looking book here, presumably produced for the trade shows. Nice to see them talking about beyond covid.
https://testandyou.org/e-book.pdf
Venable LLP, who are the correspondent for the Novacyt TradeMark filing in the US, are the largest law firm in the state of Maryland.